Peripheral α2 agonist activity results in vasoconstriction of blood vessels (as opposed to central α2 agonist activity that decreases sympathetic tone, as can be seen by the medication clonidine). This vasoconstriction may explain the acute reduction in aqueous humor flow. The increased uveoscleral outflow from prolonged use may be explained by increased prostaglandin release due to α adrenergic stimulation. This may lead to relaxed ciliary muscle and increased uveoscleral outflow. Society and culture
Names
It is sold under the brand names Alphagan, Alphagan-P, Mirvaso, Lumify, Brymont, and others. Over the counter
In July 2018, Bausch and Lomb began to market over the counter (OTC) eye drops, using brimonidines tartrate formulation in a concentration of 0.025%, as an ophthalmic vasoconstrictor under the brand name Lumify. Intended to relieve redness in the sclerae of the eyes for periods of up to eight hours at a time through its vasoconstrictive effects, Lumify was marketed as an alternative to Visine, the brand of tetrahydrozoline hydrochloride solution most commonly used for that purpose. References
Further reading
Oh DJ, Chen JL, Vajaranant TS, Dikopf MS (January 2019). "Brimonidine tartrate for the treatment of glaucoma". Expert Opin Pharmacother. 20 (1): 115–122. doi:10.1080/14656566.2018.1544241. PMID 30407890. S2CID 53240954. External links
"Brimonidine". Drug Information Portal. U.S. National Library of Medicine. "Brimonidine tartrate". Drug Information Portal. U.S. National Library of Medicine.
Several methods can be used for genetic testing that can help identity this condition,
Molecular genetic tests (or gene tests) study single genes or short lengths of DNA to identify mutations and variations that can help lead to a genetic disorder. Chromosomal genetic tests help investigate whole chromosomes or long lengths of DNA to see if there are bigger genetic changes, for example, an extra copy of a chromosome that can help cause a genetic condition. Biochemical genetic tests study the activity level and amount level of proteins; abnormalities in either can indicate changes to the DNA and result in a genetic disorder. Management
Although there has been no conclusive evidence on medications to manage the disorder, many organizations help with several aspects on living with the chronic condition, not only for the affected but also for the loved ones around them. With services like Global Genes helping contribute to this. References
Further reading
Itin P., Pittelkow M., Trichothiodystrophy: Review of sulfur-deficient brittle hair syndromes and association with the ectodermal dysplasias[1]. Journal of the American Academy of Dermatology, Volume 22, Issue 5, Pages 705–717
Rare Disorders: All you need to know. Trichothiodystrophy[2]. Copyright © 2005 Rare-Disorders.com
Sabinas brittle hair syndrome is a form of nonphotosensitive trichothiodystrophy; Brittle hair and mental deficit at NIHs Office of Rare Diseases


== External links ==